Are you Dr. Knapp?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 56 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
3100 Plaza Properties Blvd
Columbus, OH 43219Phone+1 614-383-6000Fax+1 614-383-6001
Summary
- Dr. Mark Knapp, MD is an oncologist in Columbus, Ohio. He is currently licensed to practice medicine in Ohio and Kentucky. He is affiliated with Mount Carmel West, OhioHealth Grady Memorial Hospital, and Madison Health.
Education & Training
- University of Cincinnati Medical Center/College of MedicineFellowship, Hematology and Medical Oncology, 2000 - 2003
- Ascension St Vincent Hospital IndianapolisResidency, Internal Medicine, 1997 - 2000
- University of Cincinnati College of MedicineClass of 1997
Certifications & Licensure
- OH State Medical License 2000 - 2026
- KY State Medical License 2001 - 2002
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL) Start of enrollment: 2013 Aug 01
- A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen Start of enrollment: 2014 Apr 09
- Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Start of enrollment: 2014 Mar 13
Publications & Presentations
PubMed
- 95 citationsIbrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCLAndre Goy, Radhakrishnan Ramchandren, Nilanjan Ghosh, Javier Munoz, David S. Morgan
Blood. 2019-09-26 - 18 citationsThe combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma.Nathan Fowler, Loretta J. Nastoupil, Sven de Vos, Mark Knapp, Ian W. Flinn
British Journal of Haematology. 2020-03-16 - 5 citationsIntensity modulated radiation therapy with simultaneous integrated boost based dose escalation on neoadjuvant chemoradiation therapy for locally advanced distal esopha...Ming Zeng, Fernando N Aguila, Taral Patel, Mark Knapp, Xue-Qiang Zhu
World Journal of Gastrointestinal Oncology. 2016-05-15